Scinai Immunotherapeutics Ltd. - American Depositary Shares (SCNI)

September 14, 2026 In drug development, identifying a dangerous compound is only half the challenge. The other is avoiding the premature elimination of a potentially valuable medicine. VivoSim Labs, Inc. (NASDAQ: VIVS) is targeting both problems with its NAMkind™ 3D human tissue models and predictive toxicology platform .

Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) shares rose 25.3% to $2.08 during Friday's after-market session. The market value of their outstanding shares is at $1.1 million. Corbus Pharmaceuticals

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company combining immunology therapeutic development with a revenue-generating contract development and manufacturing organization (“CDMO”), announced a strategic refocusing of its R&D portfolio following the Aug. 31 expiration and termination of its option and license arrangements with PinCell S.r.l. relating to PC111. Scinai said the decision was not driven by any new negative scientific finding regarding PC111 and will allow the company to concentrate R&D resources on its NanoAb platform while preserving capital and management capacity for its CDMO business. Scinai is advancing two IL-17 programs within the NanoAb platform, including an intradermal psoriasis program for which approximately €12 million in grant financing is under evaluation in Poland. The company also reported approximately $3.1 million in committed CDMO customer orders as of Aug. 16 and continues to pursue approximately $5 million in CDMO revenue for 2026, subject to project execution, timing, revenue recognition and additional business opportunities.

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company combining therapeutic development with a revenue-generating contract development and manufacturing organization (“CDMO”), reported first-half 2026 revenue of $949,000, up from $773,000 in the prior-year period, while committed customer orders reached approximately $3.1 million as of Aug. 16, 2026, including approximately $2.1 million already invoiced. The company is also advancing an expanded clinical manufacturing and chemistry, manufacturing and controls (“CMC”) program for a U.S.-based biopharmaceutical company, with approximately $650,000 in cash payments and advances received and substantive activities underway while a definitive agreement remains under negotiation. The program is intended to support an investigational drug product toward a U.S. investigational new drug (“IND”) submission and Phase III clinical development. Scinai continues to pursue approximately $5 million in CDMO revenue for 2026.

Scinai Immunotherapeutics (NASDAQ: SCNI) announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd., has appointed Eran Kuratz as head of supply chain and business process administration. Kuratz brings more than 30 years of leadership, supply chain and operational experience across the pharmaceutical, biotechnology, medical-device and industrial sectors. He will oversee functions including procurement, contracting, inventory management, logistics, budgeting, IT and business systems, cybersecurity and cross-functional business processes.

Scinai Immunotherapeutics (NASDAQ: SCNI) announced the appointment of Eilon Elmalem as site head of its wholly owned subsidiary Scinai Biopharma Services’ Yavne CDMO facility, effective June 14, 2026. Elmalem, who has supported the company as an external consultant for the past two years, brings more than two decades of biotechnology and pharmaceutical operations experience and will oversee site operations and engineering activities as Scinai continues expanding its contract development and manufacturing platform.

Kartoon Studios (NYSE: TOON) is gaining significant investor attention as momentum builds across the media sector following reports that investors have approved a major transaction involving Warner Bros. Discovery (NASDAQ: WBD) and Paramount Skydance (NASDAQ: PSKY), intensifying consolidation across streaming and entertainment markets.

Scinai Immunotherapeutics (NASDAQ: SCNI) announced it has entered into a securities purchase agreement with institutional and accredited investors for the sale of 5,208,333 ADSs at $0.48 per ADS, along with accompanying Series A and Series B warrants, and separately executed a warrant inducement agreement with an existing investor. The combined transactions are expected to generate approximately $2.61 million in gross proceeds, with closing anticipated on or about April 27, 2026, subject to customary conditions. The company said proceeds will support expansion of its CDMO platform, advancement of customer programs and continued investment in its immunotherapy pipeline.

Scinai Immunotherapeutics (NASDAQ: SCNI) announced that it received written notification from the Nasdaq Listing Qualifications Department on March 12, 2026, indicating it is not in compliance with the Nasdaq Capital Market’s minimum bid price requirement under Listing Rule 5550(a)(2) after its American Depositary Shares traded below $1.00 for 30 consecutive business days. The notice has no immediate impact on the listing or trading of the company’s ADSs, and Scinai has been granted a 180-day compliance period through Sept. 8, 2026, during which it may regain compliance if its closing bid price meets or exceeds $1.00 for at least 10 consecutive business days.